Stock BIAF BIOAFFINITY TECHNOLOGIES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages bioAffinity Technologies, Inc.

Equities

BIAF

US09076W1099

Market Closed - Nasdaq
Other stock markets
 21:00:00 29/04/2024 BST 		5-day change 1st Jan Change
2.53 USD +6.75% Intraday chart for bioAffinity Technologies, Inc. -2.32% +72.05%
04-01 BioAffinity Technologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
03-20 BioAffinity Technologies, Inc. announced that it has received $2.624 million in funding CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
BioAffinity Technologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
BioAffinity Technologies Closes $2.5 Million Equity Offerings
BioAffinity Technologies, Inc. Appoints Sandeep Bansal to Medical and Scientific Advisory Board
BioAffinity Technologies, Inc. Appoints Jamie Platt, Ph.D., to its Board of Directors
BioAffinity Technologies, Inc. Provides Earnings Guidance for the Year 2023 and for the Next 12 Months(fourth quarter 2023 to third quarter 2024)
BioAffinity Technologies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
BioAffinity Technologies, Inc. Appoints Dallas J. Coleman as National Director of Sales
BioAffinity Technologies Files Registration Statement for Planned Offering of Units at Assumed Price of $1.62 a Unit
BioAffinity Technologies, Inc. Announces Board Changes
BioAffinity Technologies Unit Acquires Precision Pathology Services Laboratory Assets; Shares Rise
BioAffinity Technologies, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
AMA Issues CPT Code for bioAffinity Technologies’ CyPath® Lung Test for Early-Stage Lung Cancer
BioAffinity Technologies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
BioAffinity Technologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
BioAffinity Technologies Announces Publication of Peer-Reviewed Paper on Proprietary Beads Used in CyPath Lung for Noninvasive Detection of Early-Stage Lung Cancer
BioAffinity Technologies, Inc. Appoints Julie Anne Overton as Director of Corporate Communications
Sector Update: Health Care Stocks Still Sagging Near Close
Sector Update: Healthcare
Top Midday Gainers
BioAffinity Technologies, Inc. Announces Publication of Results of Clinical Trial in Peer-Reviewed Journal Respiratory Research
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BIAF Stock
  4. News bioAffinity Technologies, Inc.
  5. Other languages